This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stattin, P. Articles by Olsson, T. Search for Related Content PubMed PubMed Citation Articles by Stattin, P. Articles by Olsson, T.

Leptin Is Associated with Increased Prostate Cancer Risk: A Nested Case-Referent Study¹

Departments of Urology and Andrology (P.S.), Public Health and Clinical Medicine (S.S., G.H., T.O.), Geriatric Medicine (A.By.), and Pathology (A.Be.), Umeå University Hospital, SE-901 85 Umeå, Sweden; International Agency for Research on Cancer (R.K.), F-69372 Lyon, France; and Department of Clinical Chemistry (U.-H.S.), Helsinki University Central Hospital, SF-00290 Helsinki, Finland

Address correspondence and requests for reprints to: Dr. Stefan Söderberg, Department of Medicine, Umeå University Hospital, SE-901 85 Umeå, Sweden. E-mail: stefan.soderberg{at}medicin.umu.se

A Western lifestyle has been implicated in the pathogenesis of prostate cancer. However, no clear association between obesity and prostate cancer has been shown. Leptin may stimulate prostate growth and angiogenesis, and receptors for leptin are present in the prostate. Leptin may, thus, be associated with increased risk of prostate cancer.

One hundred forty-nine men with prostate cancer were identified (together with 298 matched referents) who, before diagnosis, had participated in population-based health surveys in Northern Sweden. Blood pressure, body mass index, and use of tobacco were recorded. Leptin, insulin, insulin-like growth factor I (IGF-I), IGF-I-binding proteins 1–3, testosterone, and sex hormone-binding globulin were analyzed in stored samples. Their influences on prostate cancer were estimated by conditional logistic regression analysis. Prostate cancer specimens were investigated for immunoreactivity for the leptin receptor.

Relative risk (95% confidence intervals) estimates of prostate cancer over the quintiles of leptin were 1.0, 2.1 (1.1–4.1), 2.6 (1.4–4.8), 1.4 (0.7–2.7), and 1.6 (0.8–3.2). Adjustments for metabolic variables, testosterone, and IGF-I and its binding proteins did not attenuate this increased risk. Immunoreactivity for the leptin receptor was detected in normal, high-grade prostatic intraepithelial neoplasia lesions and malignant prostatic epithelium.

Moderately elevated plasma leptin concentrations are associated with later development of prostate cancer. This may be due to direct effects of leptin on prostatic intraepithelial neoplasia lesions, or to indirect actions through other mechanisms. A critical fat mass related to an interior milieu favorable for prostate cancer development seems to exist, because intermediate but not high leptin levels are related to prostate cancer risk.

This article has been cited by other articles:

				M. Dror Michaelson, M. M. Regan, W. K. Oh, D. S. Kaufman, K. Olivier, S. Z. Michaelson, B. Spicer, C. Gurski, P. W. Kantoff, and M. R. Smith Phase II study of sunitinib in men with advanced prostate cancer Ann. Onc., May 1, 2009; 20(5): 913 - 920. [Abstract] [Full Text] [PDF]

				T. Pischon, H. Boeing, S. Weikert, N. Allen, T. Key, N. F. Johnsen, A. Tjonneland, M. T. Severinsen, K. Overvad, S. Rohrmann, et al. Body Size and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3252 - 3261. [Abstract] [Full Text] [PDF]

				V. M. Chia, P. A. Newcomb, J. W. Lampe, E. White, M. T. Mandelson, A. McTiernan, and J. D. Potter Leptin Concentrations, Leptin Receptor Polymorphisms, and Colorectal Adenoma Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2697 - 2703. [Abstract] [Full Text] [PDF]

				D. J. Parekh, D. P. Ankerst, J. Baillargeon, B. Higgins, E. A. Platz, D. Troyer, J. Hernandez, R. J. Leach, A. Lokshin, and I. M. Thompson Assessment of 54 Biomarkers for Biopsy-Detectable Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1966 - 1972. [Abstract] [Full Text] [PDF]

				A. W Hsing, L. C Sakoda, and S. C Chua Jr Obesity, metabolic syndrome, and prostate cancer Am. J. Clinical Nutrition, September 1, 2007; 86(3): 843S - 857S. [Abstract] [Full Text] [PDF]

				J.-R. Zhou, L. Li, and W. Pan Dietary soy and tea combinations for prevention of breast and prostate cancers by targeting metabolic syndrome elements in mice Am. J. Clinical Nutrition, September 1, 2007; 86(3): 882S - 888S. [Abstract] [Full Text] [PDF]

				S. J. Freedland and E. A. Platz Obesity and Prostate Cancer: Making Sense out of Apparently Conflicting Data Epidemiol. Rev., May 3, 2007; (2007) mxm006v1. [Abstract] [Full Text] [PDF]

				S. J. Freedland, W. J. Aronson, B. Trock, P. Cohen, C. J. Kane, C. L. Amling, J. C. Presti Jr., M. K. Terris, and for the Shared Equal Access Regional Cancer Hospit Racial Differences in Prognostic Value of Adult Height for Biochemical Progression Following Radical Prostatectomy Clin. Cancer Res., November 1, 2005; 11(21): 7735 - 7742. [Abstract] [Full Text] [PDF]

				S. J. Freedland Obesity and Prostate Cancer: A Growing Problem Clin. Cancer Res., October 1, 2005; 11(19): 6763 - 6766. [Full Text] [PDF]

				M. J. Roth, D. N. Paltoo, P. S. Albert, D. J. Baer, J. T. Judd, J. Tangrea, and P. R. Taylor Common Leptin Receptor Polymorphisms do not Modify the Effect of Alcohol Ingestion on Serum Leptin Levels in a Controlled Feeding and Alcohol Ingestion Study Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1576 - 1578. [Abstract] [Full Text] [PDF]

				E. L. Giovannucci, Y. Liu, M. F. Leitzmann, M. J. Stampfer, and W. C. Willett A Prospective Study of Physical Activity and Incident and Fatal Prostate Cancer Arch Intern Med, May 9, 2005; 165(9): 1005 - 1010. [Abstract] [Full Text] [PDF]

				R. J. MacInnis, D. R. English, D. M. Gertig, J. L. Hopper, and G. G. Giles Body Size and Composition and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1417 - 1421. [Abstract] [Full Text] [PDF]

				M. J. Roth, D. J. Baer, P. S. Albert, T. W. Castonguay, J. F. Dorgan, S. M. Dawsey, E. D. Brown, T. J. Hartman, W. S. Campbell, C. A. Giffen, et al. Relationship Between Serum Leptin Levels and Alcohol Consumption in a Controlled Feeding and Alcohol Ingestion Study J Natl Cancer Inst, November 19, 2003; 95(22): 1722 - 1725. [Abstract] [Full Text] [PDF]

				Bibliography Scand J Public Health, November 1, 2003; 31(61_suppl): 85 - 91. [PDF]

				M. Onuma, J. D. Bub, T. L. Rummel, and Y. Iwamoto Prostate Cancer Cell-Adipocyte Interaction: LEPTIN MEDIATES ANDROGEN-INDEPENDENT PROSTATE CANCER CELL PROLIFERATION THROUGH c-Jun NH2-TERMINAL KINASE J. Biol. Chem., October 24, 2003; 278(43): 42660 - 42667. [Abstract] [Full Text] [PDF]

				P. Stattin, R. Kaaks, R. Johansson, R. Gislefoss, S. Soderberg, H. Alfthan, U.-H. Stenman, E. Jellum, and T. Olsson Plasma Leptin Is Not Associated with Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 474 - 475. [Full Text] [PDF]

				A. W. Hsing, S. Chua Jr, Y.-T. Gao, E. Gentzschein, L. Chang, J. Deng, and F. Z. Stanczyk Prostate Cancer Risk and Serum Levels of Insulin and Leptin: a Population-Based Study J Natl Cancer Inst, May 16, 2001; 93(10): 783 - 789. [Abstract] [Full Text] [PDF]